TY - JOUR
T1 - Asciminib
T2 - a new therapeutic option in chronic-phase CML with treatment failure
AU - Yeung, David T.
AU - Shanmuganathan, Naranie
AU - Hughes, Timothy P.
N1 - Funding Information:
Conflict-of-interest disclosure: T.P.H. receives research funding and honoraria from Novartis, BMS, and Takeda. N.S. receives research funding from Novartis. D.T.Y. receives research funding and honoraria from BMS and Novartis, and honoraria from BMS, Novartis, Takeda, Pfizer, and Amgen.
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/6/16
Y1 - 2022/6/16
N2 - Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.
AB - Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.
UR - http://www.scopus.com/inward/record.url?scp=85132211777&partnerID=8YFLogxK
U2 - 10.1182/blood.2021014689
DO - 10.1182/blood.2021014689
M3 - Editorial
C2 - 35468180
AN - SCOPUS:85132211777
VL - 139
SP - 3474
EP - 3479
JO - Blood
JF - Blood
SN - 0006-4971
IS - 24
ER -